A recent study proposed the silencing of the hepatic bile acid-related nuclear farnesoid x receptor (FXR), which induces the expression of genes involved in heme biosynthesis, as a potential new therapeutic approach against EPP-associated cholestasis (Dean et al., 2023). Here, NR1H4 is linked to autosomal erythropoietic protoporphyria.